Menu Search
Equities

Novo Nordisk A/S

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)438.95
  • Today's Change-16.60 / -3.64%
  • Shares traded3.34m
  • 1 Year change-54.62%
  • Beta1.2453
Data delayed at least 15 minutes, as of Jul 11 2025 15:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 17-Apr-25
  • 15-May-25
  • 19-Jun-25
  • 10-Jul-25
Select bar for recommendation details.
Recommendations10-Jul-25
Buy4
Outperform14
Hold8
Sell1
Strong Sell1

Share price forecast in DKK

The 25 analysts offering 12 month price targets for Novo Nordisk A/S have a median target of 620.00, with a high estimate of 900.00 and a low estimate of 405.00. The median estimate represents a 41.25% increase from the last price of 438.95.
High105.0%900.00
Med41.2%620.00
Low-7.7%405.00

Dividends in DKK

In 2024, Novo Nordisk A/S reported a dividend of 11.40 DKK, which represents a 21.28% increase over last year. The 22 analysts covering the company expect dividends of 12.90 DKK for the upcoming fiscal year, an increase of 13.18%.
Div growth (TTM)21.28%
More ▼

Earnings history & estimates in DKK

On May 07, 2025, Novo Nordisk A/S reported 1st quarter 2025 earnings of 6.53 per share. This result was in line with the consensus of the 9 analysts following the company and exceeded last year's 1st quarter results by 14.96%.
The next earnings announcement is expected on Aug 06, 2025.
Average growth rate+5.49%
Novo Nordisk A/S reported annual 2024 earnings of 22.63 per share on Feb 05, 2025.
Average growth rate+26.73%
More ▼

Revenue history & estimates in DKK

Novo Nordisk A/S had 1st quarter 2025 revenues of 78.09bn. This missed the 78.18bn consensus estimate of the 10 analysts following the company. This was 19.49% above the prior year's 1st quarter results.
Average growth rate+5.05%
Novo Nordisk A/S had revenues for the full year 2024 of 290.40bn. This was 25.03% above the prior year's results.
Average growth rate+23.22%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.